CAR-T therapy could “alter the treatment paradigm” of multiple sclerosis
Drug Discovery World
JANUARY 5, 2024
Kyverna Therapeutics has revealed plans to progress to Phase II trials of KYV-101 for multiple sclerosis (MS) following a green light from the US Food and Drug Administration (FDA). “This very important study will answer whether CAR T-cell therapy offers a new treatment option for patients living with MS.
Let's personalize your content